Business Context and Reporting Period
This Form 6-K filing by Globant S.A. reports on the outcomes of the Annual General Meeting (AGM) and Extraordinary General Meeting (EGM) held on May 8, 2017. The filing was submitted on May 10, 2017. The meetings addressed corporate governance, financial approvals for the fiscal year ended December 31, 2016, and amendments to the company's Articles of Association.
Key Financial Metrics
The filing references financial results for the fiscal year ended December 31, 2016, but does not provide a comprehensive breakdown of revenue, cash flow, or debt levels.
- Consolidated Net Gain: USD $35,862,000 (under EU IFRS and IFRS).
- Stand-alone Net Loss: USD $3,531,244.41 (under LUX GAAP).
- Dividend/Allocation: The stand-alone loss was resolved to be carried forward to the next financial year.
The filing text does not provide clear values for revenue, operating margins, liquidity, or debt obligations.
Material Changes and Corporate Actions
Shareholders approved several material changes and resolutions:
- Capital Increase: Authorized share capital (excluding issued capital) was increased to USD $9,035,472, represented by 7,529,560 common shares with a nominal value of USD $1.20 each.
- Share Issuance Authority: The Board of Directors was authorized to issue shares, grant options, and issue convertible instruments without pre-emptive subscription rights for existing shareholders for a period of five years from the date of the EGM.
- Meeting Schedule: The date for the annual general meeting was amended from the fourth Friday of April to any date within six months of the end of the financial year.
- Board Composition: Linda Rottenberg was appointed, and Martín Gonzalo Umaran and Guibert Andrés Englebienne were re-appointed to the Board of Directors for terms ending in 2020.
- Auditor Appointment: Deloitte Audit and Deloitte & Co S.A. were appointed as independent auditors for the 2017 fiscal year.
Guidance, Outlook, and Risks
The filing does not contain management commentary regarding future financial guidance, market outlook, or specific risk factors. The primary focus is on the ratification of past financial statements and the authorization of future capital flexibility.
Investor Verification Checklist
- Verify the impact of the authorized share capital increase on potential dilution, given the Board's power to issue shares without pre-emptive rights.
- Review the full 2016 Annual Report (Form 20-F) to analyze the discrepancy between the consolidated gain (USD $35.9M) and the stand-alone loss (USD $3.5M).
- Confirm the specific terms and vesting schedules for the stock options granted to Board members, which were ratified at the AGM.
- Monitor future filings for the actual issuance of shares under the new five-year authorization.